Incyte
Tracked across 4 events · 25 articles · First seen Jun 08, 2026 · Last active Aug 31, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Business
Impact: Incyte is acquiring Vega Therapeutics to expand its hematology portfolio with VGA039, a promising drug for bleeding disorders, which is expected to be a significant growth driver.
Jun 08, 2026 · 6 articles
Tech
Impact: Incyte is the developer and sponsor of latarcibart; positive Phase 1/2 data supports its pipeline and potential market entry.
Jul 13, 2026 · 7 articles
Regulatory
Impact: Incyte's Jakafi faces potential competition from Mimrylo, which has a broader label and may be used as first-line therapy, potentially eroding Jakafi's market share in polycythemia vera.
Aug 28, 2026 · 6 articles
Business
Impact: Incyte co-markets Olumiant with Eli Lilly; potential competitive impact from bempikibart.
Jul 13, 2026 · 6 articles
ERGEN INTELLIGENCE
Track Incyte live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard